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I NTRO D U C TIO N
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterised by seizures, mental retardation, skin lesions and hamartomatous lesions in several organs. These lesions include renal angiomyolipomas and cysts, facial angiofibromas, cardiac rhabdomyomas, subependymal giant cell astrocytomas and cortical tubers. (1) The prevalence of TSC is estimated to range from 1/6,000 to 1/9,000 due to undiagnosed or asymptomatic patients. (2) Multiple hamartomas or tumours may develop in multiple organs. The genes affected in TSC are TSC1 (located on 9q34) and TSC2 (located on 16p13.3), which are normally expressed in neuroendocrine cells and are both tumour growth suppressors. (3, 4) TSC1 and TSC2 encode the proteins hamartin and tuberin, respectively, which form the TSC1-TSC2 complex and share a common signalling pathway. Inactivation of these genes causes the development of a wide range of hamartomatous lesions. (4) Lesions formed in the brain can lead to symptoms such as seizures, intellectual disability and skin angiofibromas. (5) In this report, we present the case of a 31-year-old patient with coexistent malignant melanoma (MM), cerebral-renal angiomyolipomas and skin lesions in association with TSC.
To the best of our knowledge, the association of MM with TSC has not been previously reported in the literature.
CA S E R EPO RT
A 31-year-old man presented to the Urology Clinic at the 
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with an axial size of 25 cm in the liver. Multiple cysts in both kidneys and similar masses in the adrenal gland and spleen on the left side were also observed (Fig. 3) . A tru-cut liver biopsy was performed and findings of the histopathological examination were compatible with MM. Immunohistochemically, human melanoma black-45 (HMB-45), Melan A, S100 and vimentin were found to be positive, but HepPar-1, CD 10 and keratin were negative (Fig. 4) .
Temozolomide (200 mg/m 2 ) was applied and disease progression was observed following a four-cycle treatment, using CT of the abdomen. In spite of the four cycles of ipilimumab (3 mg/kg) administered to the patient, the response was only stable disease.
D I SCU S S IO N
TSC is a genetic disease usually caused by sporadic genetic mutations. Inheritance of the disease, with an autosomal dominant pattern, has also been reported. (1, 4) The genes affected in TSC are TSC1 and TSC2, (3) and mutations in these genes are related to various risks of malignancy. For instance, an increased incidence of TSC2 mutations has been reported in patients with renal cell carcinoma.
The TSC genes play a significant role in the phos- 
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C a s e R e p o r t e235 literature, TSC has been associated with testicular, gastric, somatostatinoma, hepatocellular, breast, giant congenital melanocytic nevus and sarcoma types of cancer (Table I) . (4, (8) (9) (10) (11) (12) (13) The transformation of a subependymal nodule into a subependymal giant cell tumour is usually a gradual process, and renal cell carcinomas may develop within dysplastic epithelial cysts in 2%-3% of these patients. (5) Our patient, in whom skin lesions were observed since childhood, was thought to have MM transformation of TSC at diagnosis (i.e. at the age of 31 years). Although TSC is not considered to be a risk factor for MM, we speculated tumour development in our patient for the following reasons: (a) the activation of neurofibromatosis type 1 gene (NF1), which has a significant role to play in the development of cutaneous neurofibromas in neurofibromatosis type 1 disease, is regulated by TSC2; (14) and (b) TSC2 regulation has a significant role in the formation of skin lesions, and mutated TSC2 may increase the risk of malignancy. (10, 15) In conclusion, we herein report the hitherto unknown association between TSC and MM. Melanoma is a heterogeneous and aetiologically complex disease. The interaction of genetic, host and environmental factors are efficacious in the development of both familial and sporadic cases of MM. As ultraviolet radiation is a particularly important environmental risk factor, (15) 
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